Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2022, with a specific transaction date of August 8, 2022. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Instrument | American Depositary Shares (ADSs) |
| Transaction Type | Acquisition (Executive Supplemental Savings Plan) |
| Volume | 1,277.800 ADSs |
| Price | $40.3100 per ADS |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It discloses an acquisition of notional ADSs by Dr. H. Barron within his GSK Executive Supplemental Savings Plan account, executed during the period when he was an Executive Director.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory compliance document detailing a single insider transaction.
Key Facts for Investor Verification
- Dr. H. Barron, currently a Non-Executive Director, acquired 1,277.800 ADSs at $40.3100 each.
- The transaction occurred on August 8, 2022, on the New York Stock Exchange.
- The acquisition was made through the GSK Executive Supplemental Savings Plan.
- The filing does not contain financial results or strategic updates for the period.